Brown Study Links Shingrix to 24% Lower Dementia Risk in 509,926 Nursing Patients
Updated
Updated · ScienceAlert · Jun 22
Brown Study Links Shingrix to 24% Lower Dementia Risk in 509,926 Nursing Patients
1 articles · Updated · ScienceAlert · Jun 22
Summary
18.8% of nursing-facility patients vaccinated with Shingrix developed dementia over four years, versus 24.6% of unvaccinated patients in a Brown-led study published in Annals of Internal Medicine.
509,926 admissions from 2017 to 2022 were analyzed, but only 8,843 patients received Shingrix within 12 months of admission, a low uptake the researchers say leaves room for prevention.
Researchers estimated the association could prevent about 1 in 17 dementia cases and said nursing-facility admission may be a practical point to offer shingles vaccination to older adults.
Because the study was observational, it cannot prove causation; the team cited possible vaccine-selection bias and said any benefit may stem from reduced shingles-related neuroinflammation or broader immune effects.
Shingrix has largely replaced Zostavax because it is more effective and longer-lasting, and the new findings add to earlier evidence linking shingles vaccination to lower dementia risk.
If multiple vaccines lower dementia risk, is a key to preventing Alzheimer's already hiding in our routine shots?
If an expensive vaccine cuts dementia risk, will brain health become a luxury only the wealthy can afford?
Shingrix Vaccine Linked to 24% Lower Dementia Risk: New Brown University Study Sparks Hope for Cognitive Protection
Overview
A major study from Brown University, published in June 2026, found that older adults in skilled nursing facilities who received the Shingrix vaccine had a 24% lower risk of developing dementia. This large-scale observational research highlights a promising link between vaccination and reduced cognitive decline, marking an important step in dementia prevention. However, because the study was observational, it can only show an association, not direct causality. While these findings are encouraging for public health, further research is needed to confirm whether Shingrix itself is the cause of the reduced dementia risk.